Kymera Therapeutics (KYMR) Other financing activities (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Other financing activities data on file, last reported at $425000.0 in Q1 2026.

• On a quarterly basis, Other financing activities rose 53.43% year-over-year to $425000.0 in Q1 2026; TTM through Mar 2026 was $61.8 million, a 231.74% increase from a year earlier, with the FY2025 full-year figure at $61.6 million, up 3809.96% from the prior year.
• Other financing activities for Q1 2026 stood at $425000.0, down from $48.8 million in the prior quarter.
• Over the last five years, Other financing activities for KYMR reached as high as $48.8 million in Q4 2025 and fell as low as -$39.1 million in Q3 2024.
• Historically, Other financing activities has averaged $4.6 million across 5 years, with a median of $277000.0 in 2025.
• Across the five-year window, Other financing activities slumped 3266.95% in 2024 and surged 707.36% in 2025, its largest moves.
• Year by year, Other financing activities stood at $2.9 million in 2022, then tumbled by 35.85% to $1.9 million in 2023, then tumbled by 532.49% to -$8.0 million in 2024, then jumped by 707.36% to $48.8 million in 2025, then tumbled by 99.13% to $425000.0 in 2026.
• Per Business Quant data, the three most recent Other financing activities figures were $425000.0 in Q1 2026, $48.8 million in Q4 2025, and $12.8 million in Q3 2025.